Q1 2017: Probi continues on its successful growth path

Highlights and significant events during the first quarter

  • Significant increase in sales and earnings driven by Nutraceutix acquisition and organic growth
  • Market launch of patented and clinically documented Probi SelectTM product range in North America
  • Start of strategic initiatives to increase production capacity and to design a new Group enterprise system (ERP)

Financial overview

Net sales 187.4 87.0 443.5
Net sales growth, local currency, % 111.1% 26.2% 103.2%
Gross margin, % 51.7% 68.3% 62.8%
EBITDA 62.4 36.9 152.6
EBITDA margin, % 33.3% 42.5% 34.4%
Operating profit (EBIT) 56.0 35.3 130.3
Net income 47.8 26.9 108.6
Earnings per share before and after dilution, SEK 4.20 2.95 11.43
Share price on closing day, SEK 419.00 114.16 475.50
Market cap on closing day 4,774.1 1,040.6 5,417.9
See note 5 for definitions of ratios not defined according to IFRS    

Invitation to Teleconference
Date: 4 May 2017
Time: 10:00 a.m.
Phone: +46 85 664 26 92
Participants from Probi:
Peter Nählstedt, CEO and Dr. Jörn Andreas, CFO

The presentation is available at www.probi.se and www.financialhearings.com

Peter Nählstedt, CEO:
Phone: +46 46 286 89 23, Email: peter.nahlstedt@probi.com
Dr. Jörn Andreas, CFO: 
Phone: +46 46 286 89 41, Email: jorn.andreas@probi.com

This information  is  information  that  Probi  AB  is  obliged  to  make  public  pursuant  to  the  EU  Market  Abuse  Regulation.  The information was submitted for publication, through the agency of the contact person set out above, at 8:00 a.m. CET on 4 May 2017. This a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

About Probi
Probi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research.
Founded by scientists in Sweden in 1991, Probi is a multinational company with four centers of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2016, Probi had net sales of MSEK 444. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has about 5,000 shareholders.


About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.



Documents & Links